Glenmark Pharmaceuticals launches TEVIMBRA in India
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The transaction is expected to close in Q2 FY 2026
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Subscribe To Our Newsletter & Stay Updated